Heart failure and high blood pressure after a myocardial infarction may require treatment that reduces aldosterone activity. Inspra contains eplerenone, a selective mineralocorticoid receptor antagonist used in adults with specific cardiovascular conditions. It limits sodium retention and helps reduce strain on the heart.
Inspra is a medicine containing eplerenone, a selective mineralocorticoid receptor antagonist. It is used in adults with specific cardiovascular conditions, including heart failure and certain conditions after myocardial infarction.
Eplerenone tablets are available in different strengths. The regimen for the selected strength should be confirmed with a healthcare professional before starting.
Treatment often begins with a lower strength, followed by cautious adjustment when blood tests remain acceptable. Dose changes are not based on symptoms alone. A person may feel well while potassium is rising, which is why laboratory monitoring is central to safe use.
The usual monitoring plan includes:
Inspra can be taken with or without food. Take it at the same time each day to create a consistent routine. If a dose is missed, take it when remembered unless the next dose is close; do not take two doses together.
Do not alter the dose because swelling, breathlessness, or blood pressure changes appear better. Heart-failure treatment is adjusted using symptoms, examination findings, blood tests, and sometimes echocardiography.
Inspra contains eplerenone as its active ingredient. Eplerenone is a selective mineralocorticoid receptor antagonist used in adults with specific cardiovascular conditions.
Eplerenone binds selectively to mineralocorticoid receptors. Aldosterone normally activates these receptors in the kidneys, encouraging sodium and water retention while promoting potassium excretion. By reducing aldosterone signalling, Inspra decreases sodium retention and limits the associated expansion of fluid volume.
The same pathway affects the cardiovascular system. Persistent aldosterone activity can contribute to vascular stiffness, myocardial fibrosis, and structural changes in the heart. Blocking the receptor helps reduce these effects in appropriate patients.
At the kidney level, eplerenone reduces aldosterone-driven sodium reabsorption. Less sodium retention can reduce fluid overload and support blood-pressure control. Potassium excretion may also fall, which explains why blood tests are needed before treatment and during dose changes.
Eplerenone is more selective than spironolactone for the mineralocorticoid receptor. This selectivity reduces the likelihood of endocrine effects such as breast tenderness or gynaecomastia, although it does not remove the risk of hyperkalaemia or kidney-related adverse effects. The RALES and EPHESUS clinical programmes helped establish the cardiovascular role of mineralocorticoid receptor antagonists in heart failure and post-infarction care [2].
Eplerenone belongs to the mineralocorticoid receptor antagonist class. The treatment decision depends on the type of heart failure, kidney function, blood-pressure readings, serum potassium, and the medicines already being taken.
Inspra may be used after a myocardial infarction when the patient has evidence of left-ventricular dysfunction and heart failure. It may also form part of treatment for chronic heart failure with reduced ejection fraction. The European Medicines Agency and MHRA prescribing information place strong emphasis on kidney function and potassium monitoring because eplerenone can raise serum potassium [1].
The medicine is not selected simply because a person has occasional high blood pressure. Its role is more specific: it blocks aldosterone in patients whose cardiovascular risk and clinical findings justify mineralocorticoid receptor antagonism.
Patients with diabetes, chronic kidney disease, dehydration, or several blood-pressure medicines need closer monitoring. Those factors can increase the likelihood of hyperkalaemia or a fall in kidney function.
Several practical mistakes can undermine treatment or increase risk:
A patient may also confuse a dose adjustment with a permanent prescription change. The intended regimen should be clear before each new strength is started.
Inspra is not suitable for everyone. A person should not take it when a prescriber has identified a contraindication such as high baseline potassium, severe kidney impairment, or a serious interaction with another medicine.
CYP3A4 is a liver enzyme that helps break down eplerenone. Strong inhibition can raise eplerenone exposure and increase adverse-effect risk. The MHRA product information gives specific restrictions for strong CYP3A4 inhibitors and potassium levels [3].
Inspra may be unsuitable when any of the following applies:
Older adults and people with reduced kidney function may need more frequent blood tests. Dehydration from vomiting, diarrhoea, fever, or poor fluid intake can also change kidney function and potassium handling.
The most clinically significant adverse effect of eplerenone is hyperkalaemia, meaning an abnormally high potassium concentration in the blood. The risk rises with impaired kidney function, diabetes, potassium supplements, potassium-sparing diuretics, and medicines that reduce renal potassium excretion.
Other reported effects include dizziness, headache, fatigue, diarrhoea, nausea, low blood pressure, and reduced kidney function. Not everyone experiences these reactions, and mild symptoms can have causes unrelated to Inspra.
High potassium may cause muscle weakness, unusual heaviness in the limbs, tingling, nausea, palpitations, or an irregular heartbeat. Some people have no warning symptoms at all. A markedly abnormal blood result requires prompt clinical management even when the patient feels normal.
Seek urgent medical attention for:
Dizziness can be more noticeable after starting treatment or when Inspra is combined with several blood-pressure medicines. Rising slowly from a chair can reduce falls, but persistent dizziness needs assessment rather than self-directed dose changes.
One practical detail is easy to miss: salt substitutes may contain potassium chloride. They can increase potassium without looking like a conventional medicine.
Eplerenone is the international non-proprietary name and the active pharmaceutical ingredient in Inspra. Eplerenone 25 mg tablets may be prescribed as a generic alternative to branded Inspra when the prescriber considers the formulation clinically suitable.
Brand and generic tablets contain the same active substance when authorised for the same strength and indication. Excipients, tablet appearance, and packaging can differ. A change between products should still be recorded in the patient’s medication list, especially when blood tests are being monitored.
The British National Formulary describes eplerenone as a selective aldosterone antagonist used in specific heart-failure settings, with dose restrictions linked to renal function and serum potassium [4].
In clinical practice, doctors usually treat Inspra as part of a wider heart-failure regimen rather than as a stand-alone solution. The aim is to reduce aldosterone-related fluid retention and cardiovascular stress while maintaining safe potassium and kidney-function results.
A cardiologist will usually want baseline blood tests before the first dose. Follow-up testing becomes more important after dose escalation, dehydration, an acute illness, or the addition of an NSAID or another potassium-raising medicine.
Patients sometimes judge treatment by how quickly ankle swelling changes. That can be misleading. Eplerenone is also used for longer-term cardiovascular protection, so the absence of an immediate sensation does not mean the treatment has no clinical purpose.
The main limitation is monitoring. Someone who cannot complete blood tests or who has unstable renal function may not be an appropriate candidate for routine treatment.
Severe palpitations, fainting, marked muscle weakness, chest discomfort, confusion, or a major reduction in urine output need urgent assessment. These symptoms can indicate hyperkalaemia, kidney injury, low blood pressure, or worsening heart failure. The MHRA safety information from 2023 places emphasis on potassium and renal monitoring, with abnormal results sometimes requiring dose interruption. Do not take an extra tablet while waiting for urgent medical advice.
Dizziness and low blood pressure can impair driving, cycling, climbing, or machinery work, especially after starting treatment or changing the dose. The EMA product information from 2016 describes dizziness and hypotension among possible adverse effects of eplerenone. Avoid hazardous tasks until you know how the medicine affects balance and alertness. Alcohol may worsen light-headedness in some people.
Pregnancy and breastfeeding require an individual assessment because human safety information for eplerenone is limited. The EMA product information from 2016 advises that treatment decisions should balance the maternal cardiovascular need against potential fetal or infant exposure. A prescriber may choose another approach depending on the heart condition and pregnancy stage. Do not start, stop, or switch treatment after discovering a pregnancy without prompt clinical advice.
Inspra can be taken at a consistent time, with or without food, according to the prescribed regimen. The NHS guidance available in 2024 supports linking the dose with a reliable daily routine. Morning dosing may be convenient when monitoring blood pressure or arranging tests, while another time may suit a patient’s existing medicines. Consistency matters more than a universal clock time.
Yes, hyperkalaemia is a recognised adverse effect of eplerenone and is the main reason for pre-treatment and follow-up blood tests. The American Heart Association guideline published in 2022 identifies potassium monitoring as a core safety measure when mineralocorticoid receptor antagonists are used in heart failure. Risk increases with kidney impairment, diabetes, potassium supplements, NSAIDs, and other renin–angiotensin system medicines. High potassium may cause no symptoms, so feeling well does not replace scheduled testing.
Both medicines block mineralocorticoid receptors and reduce aldosterone activity, but eplerenone is more selective for that receptor. Spironolactone can produce endocrine adverse effects such as breast tenderness or gynaecomastia more often, whereas eplerenone may be chosen when those effects are a concern. Eplerenone still carries a clinically important hyperkalaemia risk and may require more frequent monitoring in some patients. NICE heart-failure guidance updated in 2025 considers mineralocorticoid receptor antagonists within a broader treatment plan rather than as interchangeable tablets without review.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The first few weeks were uneventful apart from mild dizziness when I stood up quickly. My blood tests were repeated after the dose change, and the routine became easier once I kept the tablet beside my morning medicines.
I noticed less ankle swelling over several weeks, but I was tired at first and worried about the potassium warnings. One blood result meant the dose had to stay lower, so the treatment was slower to adjust than I expected.
I felt light-headed during the first few days and missed one dose because I was unsure whether to take it late. The advice was to skip the missed tablet rather than double up, and the dizziness settled after the treatment was reviewed.
